A randomized trial comparing hypofractionated and conventionally fractionated three-dimensional conformal external-beam radiotherapy for localized prostate adenocarcinoma: a report on the first-year biochemical response

Darius Norkus, Albert Miller1, Aista Plieskienė, Ernestas Janulionis, Konstantinas Povilas Valuckas
Department of Radiotherapy,
1Center of Medical Physics and Metrology, Institute of Oncology, Vilnius University, Vilnius, Lithuania

Key words: prostate cancer; radiotherapy; hypofractionation; biochemical response.

Summary. Objective. This paper describes the first-year biochemical (prostate-specific antigen [PSA]) response of 91 irradiated patients enrolled in a single-institution randomized trial comparing hypofractionated (HFRT) and conventionally fractionated (CFRT) external beam radiotherapy.

Material and methods. Forty-four patients in the CFRT treatment arm were irradiated with 74 Gy in 37 fractions (2 Gy per fraction), and 47 in the HFRT arm were treated with 57 Gy, given in 13 fractions of 3 Gy plus 4 fractions of 4.5 Gy. The clinical target volume includes the prostate and a base of seminal vesicles. The proportions of patients who reached PSA nadir (nPSA) lower than or equal to 1.0 ng/mL (nPSA1) and 0.5 ng/mL (nPSA05) were compared.

Results. There were 2 non-cancer-related deaths (1 in the CFRT and 1 in the HFRT treatment arms). Biochemical relapse after irradiation was defined in five cases (3 in the CFRT and 2 in the HFRT treatment arms) during a 12-month follow-up. The remaining 84 patients were analyzed. The proportions of patients reaching nPSA1 were 50% and 54.5% in the CFRT and HFRT treatment arms, respectively (chi-square P=0.843). The percentages of patients reaching nPSA05 were 25% and 18.2%, respectively (chi-square P=0.621). The trends toward increasing proportions of biochemical responders (both nPSA1 and nPSA05) during 12 months after radiotherapy were observed, but the difference between trends for treatment arms did not reach a statistical significance.

Conclusion. The preliminary results presented here demonstrate that HFRT schedule induces biochemical response rates comparable to those in the CFRT schedule during the first-year follow-up.

Introduction
The randomized dose-escalation trials demonstrate a significant improvement in freedom from biochemical failure (FFBF) for intermediate and high-risk prostate cancer with the increase of conventionally fractionated radiotherapy dose (1–3). Even for low-risk patients, the 10-Gy dose escalation results in about 5–7% gain in 5-year FFBF (4). Conventionally fractionated dose escalation, however, results in treatment protraction, which negatively impacts patient’s lifestyle and possibly lowers biological benefit.

Hypofractionation in the treatment of prostate cancer offers a shorter treatment course and increased convenience for patients. Shorter waiting lists are beneficial to department’s productivity. Potentially hypofractionation in the treatment of prostate cancer also offers an improved therapeutic ratio due to a presumed higher sensitivity of prostate cancer tissues to higher fraction dose. Recent publications suggested that the α/β ratio (the ratio of “intrinsic radiosensitivity” to the “repair capability” of a specified tissue) of prostate adenocarcinoma was comparable to that for late-responding normal tissue or even lower because of the slow natural turnover rates in a high proportion of these tumors (5). The estimated value for α/β is 1.5 Gy (6–8). If the α/β value for prostate is reliably lower than that for late-responding rectal damage (3 Gy), hypofractionated regimens could be designed with
fewer but larger doses, which maintain equivalent late toxicity while yielding improved tumor control. Up to date, several nonrandomized and 3 randomized trials have addressed this issue, but the data about benefit of hypofractionation in the treatment of prostate cancer are still scarce.

In 2004, the Institute of Oncology of Vilnius University initiated a prospective randomized clinical trial comparing hypofractionated (HFRT) and conventionally fractionated (CFRT) external-beam radiotherapy for localized prostate cancer. The Lithuanian Bioethics Committee (LBEC) approved the study protocol and written informed consent.

The study has five endpoints: overall survival, freedom from biochemical failure, biochemical response to treatment, acute and late toxicity. Up to date, the collection of data for the first-year biochemical response to radiotherapy was completed for evaluation. The accrued 84 patients, with a minimum follow-up of 12 months, were analyzed for biochemical response to differently fractionated radiotherapy.

**Material and methods**

The protocol was designed to randomize patients with clinically localized prostate cancer to 74 Gy in 37 fractions at 2 Gy per fraction over 7.5 weeks (conventionally fractionated radiation therapy [CFRT]) vs. 57 Gy in 17 fractions over 3.5 weeks giving 13 fractions of 3 Gy plus 4 fractions of 4.5 Gy (hypofractionated radiation therapy [HFRT]). The HFRT regimen was hypothesized to be equivalent to 81 Gy in 2-Gy fractions assuming an $\alpha/\beta$ ratio of 1.5 Gy. This regimen was also designed to maintain predicted late toxicity equivalent to about 74 Gy in 37 fractions if $\alpha/\beta$ ratio for late-responding tissues is 3 Gy and predicted acute toxicity equivalent corresponding to about 64 Gy in 32 fractions if $\alpha/\beta$ ratio for early responding tissues is 10 Gy (9). The rationale for using 13 fractions of 3 Gy plus 4 fractions of 4.5 Gy in the study arm instead of constant fraction larger than 3 Gy was to detect an excess of acute toxicity and eliminate systematic patient setup error during the first 2 weeks of moderately hypofractionated irradiation.

The main inclusion criteria were as follows: prostate adenocarcinoma of low- and intermediate-risk group, with risk of seminal vesicle and/or pelvic lymph node involvement of less than 15% regarding Partin’s nomograms and Roach formula, no hormonal therapy or surgical castration before radiotherapy. Only three patients with stage T3A cancer of the prostate were included in study, because they all had refused the advised hormonal therapy. Forty-four patients were treated with CFRT and 47 with HFRT. The distribution of the patients by clinical T stage, by biopsy Gleason score, and initial PSA level is shown in Table 1.

The clinical target volume (CTV) included the entire prostate and the base of seminal vesicles. The planning target volume (PTV) margin of 8–10 mm was added to CTV in all directions. Conventional patient positioning using skin marks and lasers was used followed by weekly portal imaging and/or repeated simulations matched with digitally reconstructed radiographs (DRRs). Three-dimensional conformal radiotherapy with five-field technique (antero-posterior, 2 lateral and 2 posterior oblique fields) with the 15 or 25 MV MLC collimated photon beams were used for treatment planning and delivery. The prescribed dose was specified to the isocenter. The minimal dose (Dmin) aimed to deliver to the PTV was 95%. The maximum dose (Dmax) within the plan was 107%. For the rectum and bladder, Dmax $\leq$95% and Dmax $\leq$100%, respectively, were allowed. For the rectum, the following rules were considered appropriate: V90 (i.e. the rectal volume receiving 90% of the prescription dose) and V75 (i.e. the rectal volume receiving 75% of the prescription dose) should be $\leq$30% and $\leq$50%, respectively. The same constraints were used for bladder – V90 and V75.

Patients were evaluated weekly for 12 weeks starting from the beginning of irradiation. PSA tests were performed every 3 months during the first year after irradiation and every 6 months later.

**Table 1. Patient initial PSA and tumor characteristics**

| Parameter           | CFRT | HFRT |
|---------------------|------|------|
| Initial PSA ≤10     | 44   | 47   |
| Initial PSA 11–20   | 0    | 0    |
| Initial PSA >20     | 0    | 0    |
| T1                  | 16   | 20   |
| T2                  | 26   | 26   |
| T3                  | 2    | 1    |
| Gleason score ≤6    | 44   | 45   |
| Gleason score 7     | 0    | 2    |
| Gleason score 8–10  | 0    | 0    |

Descriptive statistics were used to characterize the patient age, disease stage, initial PSA, Gleason score. The same methods were used to report patient proportions with PSA nadir of $\leq$1.0 ng/mL (nPSA1) and $\leq$0.5 ng/mL (nPSA05). The chi-square test was used to assess differences in nPSA1 and nPSA05 prevalence ratio.

Medicina (Kaunas) 2009; 45(6)
Results

All 91 patients received radiotherapy according to the protocol. The median age of the patients at the beginning of treatment was 63 years (range, 53–75) in the HFRT and 65 years (range, 50–78) in the CFRT treatment arm. There were 2 deaths due to non-cancer disease (1 in the CFRT and 1 in the HFRT treatment arms). Biochemical relapse after irradiation was defined in five cases (3 in the CFRT and 2 in the HFRT treatment arms) during a 12-month follow-up. The American Society for Therapeutic Radiology and Oncology (ASTRO) definition of biochemical progression was used to report the PSA relapse (10). The remaining 84 patients had at least 12 months of follow-up after the completion of irradiation and were analyzed for PSA response to the treatment (Table 2).

The nPSA1 and nPSA05 prevalence ratio was calculated monthly in both treatment arms and plotted in separate diagrams (Figs. 1 and 2). There was no significant difference in proportions of patients between CFRT and HFRT treatment arms, who achieved either nPSA1 or nPSA05. At 12 months after the completion of the irradiation, the proportions of patients reaching nPSA1 were 50% and 54.5% in the CFRT and HFRT treatments arms, respectively (chi-square P=0.843). The percentages of patients reaching nPSA05 were 25% and 18.2%, respectively (chi-square P=0.621). The trends toward increasing proportions of biochemical responders (both nPSA1 and nPSA05) during 12 months after radiotherapy were observed, but the difference between trends for CFRT and HFRT treatment arms did not reach statistical significance.

Discussion

The low α/β values have been proposed for prostate cancer in recent years. However, several investigators have questioned the low α/β value, and clinical data on hypofractionation in prostate cancer are sparse. Several reports on hypofractionation for prostate radiotherapy from nonrandomized and randomized trials have been published to date. The available data are summarized in Table 3. Despite marked differences in dose prescription, treatment planning, delivery, verification and result interpretation methods, one may conclude from these (11–14, 16–20) nonrandomized trials that the results compare favorably with those achieved in conventionally fractionated radiotherapy series.

Three further series including two randomized trials used low radiation doses considered inappropriate today (21, 22). Only the results regarding acute toxicity from ongoing randomized trial have been reported recently (23). No results of efficacy from this study will be available for 2 to 4 years.

It is well established that pretreatment PSA, PSA doubling time (PSADT), stage, grade, dose, and post-treatment nPSA are all predictors of biochemical relapse in selected groups of men treated with radiothe-

Table 2. Numbers of patients who reached nPSA1 and nPSA05

| Arm  | Break of cutoff value | 1 month | 3 months | 6 months | 9 months | 12 months |
|------|-----------------------|---------|----------|----------|----------|-----------|
|      | nPSA ≤1.0             |         |          |          |          |           |
| CFRT | Yes                   | 4       | 9        | 17       | 18       | 20        |
|      | No                    | 36      | 31       | 23       | 22       | 20        |
| HFRT | Yes                   | 0       | 7        | 11       | 14       | 24        |
|      | No                    | 44      | 37       | 33       | 30       | 20        |
|      | chi-square test P value | 0.1017 | 0.624    | 0.089    | 0.214    | 0.843     |
|      | nPSA ≤0.5             |         |          |          |          |           |
| CFRT | Yes                   | 1       | 2        | 5        | 7        | 10        |
|      | No                    | 39      | 38       | 35       | 33       | 30        |
| HFRT | Yes                   | 0       | 1        | 2        | 5        | 8         |
|      | No                    | 44      | 43       | 42       | 39       | 36        |
|      | chi-square test P value | 0.291  | 0.501    | 0.187    | 0.64     | 0.621     |

CFRT – conventionally fractionated external-beam radiotherapy, HFRT – hypofractionated external beam radiotherapy.
Fig. 1. Change of nPSA ≤1.0 ng/mL prevalence ratio in patient groups during 12 months after irradiation

Fig. 2. Change of nPSA ≤0.5 ng/mL prevalence ratio in patient groups during 12 months after irradiation
There are several studies to demonstrate the overwhelming predictive power of posttreatment nPSA for distant failure and death from prostate cancer (24, 25). We used these criteria (nPSA1 and nPSA05) to analyze and compare the efficacy of both conventionally fractionated and hypofractionated radiotherapy schedules in our study. Our early results after 12-month follow-up suggest that hypofractionation for prostate cancer could be as effective as conventionally fractionated radiotherapy.

There is some chance that the absence of daily target localization in this study could cause difficulties in comparison of biochemical tumor response between patient groups after a longer follow-up period because of the higher probability of geographical miss with decreased number of fractions. Though, with CTV to PTV margin of 10 mm in many centers using 3D conformal radiotherapy, daily prostate movements are generally accommodated.

**Conclusions**

The first results of study presented here demonstrate that short-course hypofractionation schedule is feasible and induces biochemical response rates comparable to those in the conventional schedule during the first-year follow-up. Extended follow-up is needed to justify safety and efficacy of our fractionation schedule in the long term.

---

**Table 3. Long-term results from nonrandomized and randomized hypofractionation on prostate cancer trials**

| Author              | Total dose (Gy)/ Number of fractions/ Fraction size (Gy) | EQD20% if α/β 1.5/3/10 Gy (Gy) | FFBF (%) [Follow-up years] |
|---------------------|-----------------------------------------------------------|--------------------------------|----------------------------|
| Kupelian et al. (11, 12) | 70/28/2.5                                                  | 80/77/73                       | 85‡, 88‡‡ [5]               |
| Tsuji et al. (13)   | 66/20/3.3                                                  |                                | 83.2 [5]                   |
| Kitamura et al. (14) | 65/26/2.5, 70/28/2.5                                      | 74/71.5/68, 80/77/73           | 91.7 [2.5], 89.4 [1.5]    |
| Soete et al. (15)   | 56/16/3.5                                                  | 80/73/63                       | ND                         |
| Ritter et al. (16)  | 64.7/22/2.94, 58.08/16/3.36, 51.6/12/4.3                 | 82/77/70, 85/77/66, 85.5/75/61 | 96‡‡ [2]                   |
| Junius et al. (17)  | 66/25/2.64                                                | 78/74/69.5                     | 92‡, 100‡‡ [1]             |
| Martin et al. (18, 19) | 60/20/3                                                  | 77/72/65                       | 76‡ [2], 97‡‡ [3]          |
| Madsen et al. (20)  | 33.5/5/6.7                                                | 78/65/47                       | 70‡, 90‡‡ [2]              |
| Leborgne et al. (21) | 80/40/2, 60/20/3, 63/20/3.15                            | 80/80/80, 77/72/65, 84/77.5/69 | ND                         |

EQD20% – total biologically equivalent dose in 2 Gy fractions (if α/β 1.5 Gy, 3 Gy, and 10 Gy).

‡‡‡ASTRO definition of biochemical progression; ‡‡‡“PSA + 2 ng/mL” definition of biochemical progression;

Risk of 5-year clinical and/or biochemical progression; ND – no data.
Hipofrakcionuota ir įprastai frakcionuota trimatė konforminė neišplėtusio prostatos vėžio spindulinių terapijų. Pirmųjų metų biocheminio atsakos įvertinimas

Darius Norkus, Albert Miller¹, Aista Plieskienė, Ernestas Janulionis, Konstantinas Povilas Valuckas
Vilniaus universiteto Onkologijos instituto Aukštųjų energijų spindulinės terapijos skyrius,
¹Medicinos fizinės ir metrologijos centras

Raktažodžiai: prostatos vėžys, spindulinių terapijų, hipofrakcionavimas, biocheminis atsakas.

Santrauka. Tikslas. Išanalizuoti vienoje institucijoje vykdyto randomizuoto klinikinio tyrimo rezultatus ir palyginti hipofrakcionuotą (HFRT) ir įprastai frakcionuotą (CFRT) neišplėtusio prostatos vėžio išorinė spindulinių terapijų, įvertinti 91 liginio biocheminių atsakų į gydymą per pirmuosius metus.

Tyrimo medžiaga ir metodai. CFRT taikyta 44 liganims, švitinta prostata ir sėklinių pūslelių pagrindas (CTV) 37 frakcijos po 2,0 Gy iki suminės 74 Gy dozės. HFRT taikyta 47 liganims, toks pat taikinys (CTV) švitintas 13 frakcijų po 3,0 Gy ir 4 frakcijos po 4,5 Gy iki suminės 57 Gy dozės. Palygintos liginio, kuriems nustatytas PSA nudas (nPSA) lygus arba mažesnis už 1,0 ng/ml (nPSA1) ir 0,5 ng/ml (nPSA05), proporcijos CFRT ir HFRT grupėse.

Rezultatai. Per 12 mėnesių nuo spinduliniu gydymo pabaigos du ligoniai mirė nuo kitų priežasčių, nesusijusių su prostatos vėžiu (po vieną CFRT ir HFRT grupėse), užfiksuoti penki biocheminio ligos progresavimo atvejai (3 – CFRT ir 2 – HFRT grupėse). Likusiems 84 liganims įvertintas PSA atsakas į gydymą. CFRT grupėje nPSA1 nustatytas 50 proc. liganų, HFRT – 54,5 proc. (chi-square p=0,843), nPSA05 nustatytas 25 ir 18,2 proc. liganų HFRT ir CFRT, attitinkamai (chi-square p=0,621). Per 12 mėnesių abiejose grupėse pastebėta akivaizdūs liginų, kuriems nustatytas biocheminis atsakas (tiek nPSA1, tiek ir nPSA05) skaičiaus augimo tendencija, tačiau statistiškai reikšmingo skirtumo tarp grupių nenustatyta.

Išvada. Ankstyvijoje šio klinikinio tyrimo duomenys HFRT ir CFRT tiriamųjų grupėse rodo panašų biocheminių atsakų per pirmuosius metus po spinduliniu gydymo.

Adresas susirašinėti: D. Norkus, VU Onkologijos instituto Aukštųjų energijų spindulinės terapijos skyrius, Santarų k., 08660 Vilnius. El. paštas: dnorkus@takas.lt

References
1. Lyons JA, Kupelian PA, Mohan DS, Reddy CA, Klein EA. Importance of high radiation doses (72 Gy or greater) in the treatment of stage T1–T3 adenocarcinoma of the prostate. Urology 2000;55:85-90.
2. Pollack A, Smith LG, von Eschenbach AC. External beam radiotherapy dose-response characteristics of 1127 men with prostate cancer treated in the PSA era. Int J Radiat Oncol Biol Phys 2000;48:507-12.
3. Zelefsky MJ, Fuku Z, Hunt M, Lee HT, Lombardi D, Ling CC, et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 2001;166:876-81.
4. van Tol-Geerdink JJ, Stalmeier PF, Pasker-de Jong PC, Huijzena H, van Lin EN, Schimmel EC, et al. Systematic review of the effect of radiation dose on tumor control and morbidity in the treatment of prostate cancer by 3D-CRT. Int J Radiat Oncol Biol Phys 2006;64:5343-5.
5. Haustermans K, Fowler JF. A comment on proliferation rates in human prostate cancer [Letter]. Int J Radiat Oncol Biol Phys 2000;48:297.
6. Brenner DJ, Hall EJ. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 1999;43:1095-101.
7. Fowler JF, Chappell RJ, Ritter MA. Is the α/β ratio for prostate tumors really low? Int J Radiat Oncol Biol Phys 2001;50:1021-31.
8. Brenner DJ, Martinez AA, Edmundson GK, Mitchell C, Thames HD, Armour EP. Direct evidence that prostate tumors show high sensitivity to fractionation (low α/β ratio) comparable to late-responding normal tissue. Int J Radiat Oncol Biol Phys 2002;56:6-13.
9. Joiner MC, Bentzen SM, Baumann M. Time-dose relationships: the linear-quadratic approach and the model in clinical practice. In: Steel GG, editor. Basic clinical radiobiology. 3rd ed. London: Arnold; 2002. p. 120-46.
10. American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 1997;37:1035-41.
11. Kupelian PA, Reddy CA, Klein EA, Willoughby TR. Short-course intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: preliminary results on late toxicity and quality of life. Int J Radiat Oncol Biol Phys 2001;51:988-93.
12. Kupelian PA, Willoughby TR, Reddy CA, Klein EA, Mihalov RN. Hypofractionated intensity modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. Int J Radiat Oncol Biol Phys 2000;48:297.
Hypofractionation for prostate cancer

Phys 2007;63:1424-30.
13. Tsuji H, Yanagi T, Ishikawa H, Kamada T, Mizoe JE, Kanai T, et al. Hypofractionated radiotherapy with carbon ions beams for prostate cancer. Int J Radiat Oncol Biol Phys 2005;63:1153-60.
14. Kitamura K, Shirato H, Shinohara N, Harabayashi T, Onimaru R, Fujita K, et al. Reduction in acute morbidity using hypofractionated intensity-modulated radiation therapy assisted with a fluoroscopic real-time tumor-tracking system for prostate cancer: preliminary results of a phase I/II study. Cancer J 2003;9:268-76.
15. Soete G, Arcangeli S, De Meerleer G, Landoni V, Fonteyne V, Arcangeli G, et al. Phase II study of a four-week hypofractionated external beam radiotherapy regimen for prostate cancer: report on acute toxicity. Radiother Oncol 2006;80:78-81.
16. Ritter MA, Forman JD, Kupelian PA, Petereit DG, Lawton C, Walker W, et al. A Phase I/II trial of dose-per-fraction escalation for prostate cancer. Int J Radiat Oncol Biol Phys 2007;69:S174.
17. Junius S, Haustermans K, Bussels B, Oyen R, Vanstraelen B, Depuydt T, et al. Hypofractionated intensity modulated irradiation for localized prostate cancer: results from a phase I/II feasibility study. Radiat Oncol 2007;2:29-36.
18. Martin JM, Bayley A, Bristow R, Chung P, Crook J, Gospodarowicz M. A prospective study of hypofractionated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2006;66:S35-6.
19. Martin JM, Rosewall T, Bayley A, Bristow R, Chung P, Crook J, et al. Phase II trial of hypofractionated image-guided intensity-modulated radiotherapy for localized prostate adenocarcinoma. Int J Radiat Oncol Biol Phys 2007;69(4):1084-9.
20. Madsen BL, Hsi RA, Pham HT, Fowler JF, Esagui L, Corman J. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.4 Gy in five fractions for localized disease: first clinical trial results. Int J Radiat Oncol Biol Phys 2007;67:1099-105.
21. Lukka H, Hayter C, Warde P, Morris J, Julian J, Gospodarowicz M. A randomized trial comparing two fractionation schedules for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys 2003;57:S126.
22. Yeh EE, Fraser RJ, McGowan RE, Botten RJ, Di Matteo AC, Roos DE, et al. Evidence for efficacy without increased toxicity of hypofractionated radiotherapy for prostate carcinoma: early results of a phase III randomized trial. Int J Radiat Oncol Biol Phys 2003;55:943-55.
23. Pollack A, Hanlon AL, Horwitz EM, Feigenberg SJ, Konski AA, Movsas B, et al. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. Int J Radiat Oncol Biol Phys 2006;64:518-26.
24. Hanlon AL, Diratzouian H, Hanks GE. Posttreatment prostate-specific antigen nadir highly predictive of distant failure and death from prostate cancer. Int J Radiat Oncol Biol Phys 2002;53(2):297-303.
25. Cheung R, Tucker SL, Kuban DA. First-year PSA kinetics and minima after prostate cancer radiotherapy are predictive of overall survival. Int J Radiat Oncol Biol Phys 2006;66(1):20-4.